Sertraline

Generic Name: Sertraline

Brand Names: Zoloft

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇Cl_₂N

CAS Number: 79617-96-2

Unique Ingredient Identifier: QUC7NX6WMB

Background: Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
...

Indication: Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety di...

Associated Conditions: Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)

Associated Therapies: -

Clinical Trials

Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania

Phase 4

Completed

Conditions: Impulse Control Disorders

First Posted Date: 2005-07-11

Last Posted Date: 2008-05-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 75

Registration Number: NCT00118014

Locations: 🇺🇸
Massachusetts General Hospital - OCD Clinic, Charlestown, Massachusetts, United States

Treatment of Adolescent Suicide Attempters (TASA)

Phase 2

Completed

Conditions: Suicide, Attempted
Depression

First Posted Date: 2004-03-26

Last Posted Date: 2020-06-22

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 120

Registration Number: NCT00080158

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Columbia University at the New York State Psychiatric Institute, New York, New York, United States
🇺🇸
New York University Child Study Center, New York, New York, United States

and more 3 locations

Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure

Phase 2

Completed

Conditions: Depression
Heart Failure, Congestive
Chronic Heart Failure

Interventions: Drug: Placebo
Drug: Sertraline

First Posted Date: 2004-02-24

Last Posted Date: 2013-02-27

Lead Sponsor: Duke University

Target Recruit Count: 469

Registration Number: NCT00078286

Locations: 🇺🇸
Duke Medical Center, Durham, North Carolina, United States

Treatment of Cholestatic Pruritus With Sertraline

Phase 2

Completed

Conditions: Hepatitis C
Liver Cirrhosis, Biliary
Pruritus

First Posted Date: 2003-04-16

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 40

Registration Number: NCT00058903

Locations: 🇺🇸
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

Improving Retention of Hispanics Receiving Antidepressant Therapy

Not Applicable

Completed

Conditions: Depression
Depressive Disorder

Interventions: Drug: Sertraline
Drug: Venlafaxine Extended Release

First Posted Date: 2003-04-08

Last Posted Date: 2013-08-20

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 50

Registration Number: NCT00057642

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Study of Pharmacotherapy of Psychotic Depression

Phase 3

Completed

Conditions: Major Depressive Disorder With Psychotic Features

Interventions: Drug: Olanzapine
Other: placebo
Drug: Sertraline

First Posted Date: 2003-03-17

Last Posted Date: 2013-08-02

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 259

Registration Number: NCT00056472

Locations: 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇨🇦
University of Toronto, Toronto, Ontario, Canada
🇺🇸
Cornell University, New York, New York, United States

and more 1 locations

Evaluation of Stress Disorders

Phase 4

Completed

Conditions: Acute Traumatic Stress Disorders
Post-Traumatic Stress Disorders

First Posted Date: 2002-12-20

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 80

Registration Number: NCT00050804

Locations: 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States

Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD)

Phase 1

Completed

Conditions: Dementia

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 30

Registration Number: NCT00001777

Locations: 🇺🇸
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States

Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder

Phase 1

Completed

Conditions: Premenstrual Syndrome

Interventions: Other: Treatment as usual (TAU)
Drug: Sertraline

First Posted Date: 2002-11-13

Last Posted Date: 2016-01-12

Lead Sponsor: Yale University

Target Recruit Count: 66

Registration Number: NCT00048854

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Treatment Outcome of Vascular Depression

Completed

Conditions: Depression
Depressive Disorder

Interventions: Drug: Sertraline

First Posted Date: 2002-09-11

Last Posted Date: 2017-10-31

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 208

Registration Number: NCT00045773

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy